Shares in February 2007 recommendation Group NBT have bounced back, after a small tumble to below 200p earlier this year, as the business proves its resilience and growth credentials.
Fresh results from the internet domain name expert for the year to June show it fizzing with health, with sales swelling 58% to £35.3m, boosted by 19% organic growth and the first major contribution from January 2007 acquisition Ascio. Many of Ascio’s customers have now been ‘migrated’ over to the group’s domain name management service, Platinum, which makes up 45% of revenues and grew 38% year on year.
The group remains strongly cash generative and £7.8m flowed into the business during the year, after a 49% increase in profits before tax and exceptionals to £5.5m. Having topped up cash balances to £4.7m and trimming debts to £4m, the group returned to a net cash position.
All divisions are performing as planned, with managed hosting increasing revenues 43%, as factors such as the growth in online shopping and penetration of broadband drives new custom. The reseller arm inherited from Ascio, which provides domain name service to internet service providers and telecoms companies, enjoyed a 20% sales increase, as it began to extend into new markets.
Online services remained flat, but continue to generate high margins and feed other parts of the business. Finally, last year’s other acquisition, brand protection specialist Envisional, remains loss-making but was relaunched a month ago, and chief executive Geoff Wicks says, ‘We sold a few, but it’s early days and I’m confident that there is a big market for this.’
Outstripping a fast-growing market and with strong levels of recurring revenues, Group NBT is proving its defensive capabilities and is conservatively forecast by house broker Numis to make 16.2p of earnings per share this year. The shares therefore look unfairly undervalued. Buy.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
Market cap: £64.35m
PE Forecast: 14.2
Share price: 253.5p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.